Biomarkers in osteoarthritis: current status and outlook — the FNIH Biomarkers Consortium PROGRESS OA study

Biomarkers in osteoarthritis: current status and outlook — the FNIH Biomarkers Consortium PROGRESS OA study

Currently, no disease-modifying therapies are approved for osteoarthritis (OA) use. One obstacle to trial success in this field has been our existing endpoints’ limited validity and responsiveness. To overcome this impasse, the Foundation for the NIH OA Biomarkers Consortium is focused on investigat...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Skeletal radiology 2023-11, Vol.52 (11), p.2323-2339
Hauptverfasser: Hunter, David J., Collins, Jamie E., Deveza, Leticia, Hoffmann, Steven C., Kraus, Virginia B.
Format: Artikel
Sprache:eng
Schlagworte:
Arthritis
Biomarkers
Cartilage
Clinical trials
Consortia
Drugs
FDA approval
Imaging
Knee
Magnetic resonance imaging
Medicine
Medicine & Public Health
Nuclear Medicine
Orthopedics
Osteoarthritis
Pain
Pathology
Phase transitions
Radiology
Review
Review Article
Success
Validity
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Currently, no disease-modifying therapies are approved for osteoarthritis (OA) use. One obstacle to trial success in this field has been our existing endpoints’ limited validity and responsiveness. To overcome this impasse, the Foundation for the NIH OA Biomarkers Consortium is focused on investigating biomarkers for a prognostic context of use for subsequent qualification through regulatory agencies. This narrative review describes this activity and the work underway, focusing on the PROGRESS OA study.
ISSN:0364-2348
1432-2161
DOI:10.1007/s00256-023-04284-w